Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

Calcitonin gene–related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin gene–related peptide receptor antagonist that may be effective in acute migraine treatment.

Continue reading

June is National Migraine & Headache Awareness Month

Bring awareness and recognition of headache disorder as a legitimate neurobiological disease and help make individuals with headache disorder know that there are new treatments available. Read about the AAPM Foundation's...
Continue reading
Topics:

FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device

Theranica, a bio-medical technology company developing advanced electroceuticals for migraine and other pain disorders, announced today that the U.S. Food and Drug Administration (FDA) granted a De Novo request for its smartphone-controlled electroceutical, Nerivio Migra®, utilizing Remote Electrical Neuromodulation for the acute treatment of migraine. 

Continue reading

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Trial

There is a significant unmet need for novel effective well‐tolerated acute migraine treatments. REN is a novel acute migraine treatment that stimulates upper arm peripheral nerves to induce conditioned pain modulation – ...
Continue reading

Why Is Migraine More Common in Women? One Protein May Hold the Key

In research published online April 8 in the Journal of Neuroscience, the calcitonin gene-related peptide (CGRP) is implicated in the development of migraine symptoms caused pain responses in female rodents, but not in males, when introduced into the meninges, the protective tissue layers surrounding the brain. 

Continue reading

TRP Channels and Migraine: Recent Developments and New Therapeutic Opportunities.

Migraine is the second-most disabling disease worldwide, and the second most common neurological disorder. Attacks can last many hours or days, and consist of multiple symptoms including headache, nausea, vomiting, hypersensitivity to stimuli such as light and sound, and in some cases, an aura is present.

Continue reading
Topics:

2019 AAPM Meeting Highlights from Practical Pain Management

Read articles about the latest pain research present at AAPM35 in Denver, March 6-10, 2019. 

Continue reading

Become part of this distinguished, multimodal, interdisciplinary community.

Join AAPM